SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP
On July 2, 2021, Kiromic closed a public offering of 8 million shares of common stock priced at $5.00 per share, conducted pursuant to a registration statement filed with the U.S. Securities and Exchange Commission on June 25, 2021 (the “Offering”). On August 13, 2021, the Company issued a press release which made passing reference to “clinical hold issues” affecting the Company’s Investigational New Drug applications for two immunotherapy products but did not otherwise expand on what those issues were. The press release stated, in relevant part, under the heading Events occurring after June 30, 2021 until August 13, 2021: “Communications with the FDA -- Supported by IQVIA, instead of simply addressing the FDA’s questions with a written response only (WRO), we took the decision to apply for a Type A meeting with the FDA. The Type A meeting will address the clinical hold issues and will allow us to discuss path toward our first-in-human dosing.”
- NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. (Kiromic or the Company) (NASDAQ: KRBP).
- Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
- The investigation concerns whether Kiromic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.